QuidelOrtho Corporation (NASDAQ:QDEL) Q4 2023 Earnings Call Transcript

Douglas Bryant: We’re definitely going to go through more detail. Yeah. And so, we’re going to attempt to show on March 20th, what the initiatives are, what we’re working on, what the milestones are, so that our investors can know that we’re on track with what we say. But I would guess [Multiple Speakers] in terms of revenue margin, it would be over probably a three-year window at this stage.

Patrick Donnelly: Okay. Thanks, Doug.

Operator: Thank you for your question. Final question is from the line of John Sourbeer with UBS. Your line is now open.

John Sourbeer: Hi. Thanks for taking the question. Just on the Savannah launch, do you still think this has the potential for 250 million revenues three years post-launch or how should we think about this over the long term?

Douglas Bryant: I think that’s true. I think you probably heard me comment earlier about the 1,000 placements, et cetera. I think we achieved what we set out to do in 2024. We’ll have a really nice start to it. And so, I don’t really see that the 250 will be something that will need to change the forecast that is.

John Sourbeer: Appreciate it. And then just a follow-up here on a clarifying thing, just to confirm you’re still including the US donor screening business. What’s the impact in the guidance there and just any color on when that would be actually wound down?

Joseph Busky: Yeah. It’s a good question. It’s in the guidance. And I think as Doug said earlier, if you were to pull it out, it’s about a point impact — favorable impact on non-respiratory revenue, and there will be a favorable impact on EBITDA margin as well. We’ll talk more about that on Investor Day, and we’ll give a little more color.

John Sourbeer: Thanks for taking the question.

Operator: Thank you for your question. There are no additional questions waiting at this time, so that will conclude the conference call. Thank you for your participation. You may now disconnect your lines.

Douglas Bryant: Thanks.